Mereo BioPharma (MREO) Net Equity Issued and Repurchased (2023 - 2025)
Mereo BioPharma (MREO) posted quarterly Net Equity Issued and Repurchased of $39000.0 for Q4 2025, down 99.66% on a QoQ basis from $11.6 million in Q3 2023.
Mereo BioPharma (MREO) Net Equity Issued and Repurchased (2023 - 2025) Analysis & Trends
Mereo BioPharma (MREO) has reported Net Equity Issued and Repurchased for 2 consecutive years, with $39000.0 the latest figure, recorded in Q4 2025.
- Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $39000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $39000.0 (down 99.66% YoY) and the FY2025 annual result came in at $39000.0, down 99.92% from the prior year.
- Net Equity Issued and Repurchased declined to $39000.0 in Q4 2025 per MREO's latest filing, from $11.6 million in the prior quarter.
- Over the last five years, Net Equity Issued and Repurchased for MREO reached as high as $11.6 million in Q3 2023 and fell as low as $39000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 163.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 141.90 Mn |
| 10 | Mereo BioPharma | 232.52 Mn | 232.52 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 39,000.00 |
| Dec 31, 2025 | 39,000.00 |
| Sep 30, 2023 | 11.61 Mn |
| Sep 30, 2023 | 11.61 Mn |